Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Brensocatib in Renal Impairment
NCT05673603Phase 1Completed
- Sponsor
- Insmed Incorporated
- Start
- Jul 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of brensocatib in Non-cystic fibrosis bronchiectasis (NCFB) (4 arms), sponsored by Insmed Incorporated. Primary endpoints: Area Under the Plasma Concentration Time Curve of Brensocatib, Maximum Observed Plasma Concentration of Brensocatib and 2 more. Started Jul 2021; status: completed.
02
Drugs
brensocatib
03
Conditions
Non-cystic fibrosis bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT05673603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05673603.